Immunic, Inc. Common Stock vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| IMUX | LLY | |
|---|---|---|
| Market Cap | $178.88 million | $1.02 trillion |
| Revenue (TTM) | — | $79.67 billion |
| Net Income (TTM) | — | $26.71 billion |
LLY leads on 1 of 1 size & scale factors.
Valuation
| IMUX | LLY | |
|---|---|---|
| P/E Ratio | — | 38.58 |
| Price / Book | — | 30.24 |
| Price / Sales | — | 12.86 |
IMUX and LLY split the valuation factors evenly.
Profitability
| IMUX | LLY | |
|---|---|---|
| Net Margin | — | 33.53% |
| Return on Equity | — | 78.84% |
IMUX and LLY split the profitability factors evenly.
Dividend
| IMUX | LLY | |
|---|---|---|
| Dividend Yield | — | 0.60% |
| Payout Ratio | — | 23.23 |
IMUX and LLY split the dividend factors evenly.
Risk & Sentiment
| IMUX | LLY | |
|---|---|---|
| Short Interest | 2.84% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: IMUX overview, IMUX financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.